Cathay International Holdings Ld Update on renewal of Cross Guarantee Agreement (9918B)
12 June 2019 - 8:59PM
UK Regulatory
TIDMCTI
RNS Number : 9918B
Cathay International Holdings Ld
12 June 2019
Cathay International Holdings Limited ("Cathay" or the
"Company")
Update on renewal of Cross Guarantee Agreement
between Jilin Haizi and Lansen's subsidiaries
Hong Kong, 12 June 2019 - Cathay International Holdings Limited
(LSE: CTI.L), an operator and investor in the growing healthcare
sector in the People's Republic of China, announces its subsidiary,
Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), has
announced today that, with reference to the proposed renewal of the
2016 cross guarantee agreement (subject to the approval of Lansen's
independent shareholders) as announced on 3 May 2019, Lansen
requires additional time to finalize the information to be included
in the circular relating thereto, it is expected that the date of
despatch of the circular to Lansen's shareholders will be postponed
to on or before 21 June 2019.
The full text of the Lansen Announcement can be found at
http://www3.hkexnews.hk/listedco/listconews/SEHK/2019/0612/LTN20190612663.pdf
and will also be made available at the Announcements & Notices
section of Lansen's homepage at
http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited
Eric Siu (Finance Director) Tel: +852 2828 9289
Patrick Sung (Director and Controller)
Consilium Strategic Communications
Mary-Jane Elliott/ Matthew Neal / Lindsey Neville Tel: +44 (0)
203 709 5700
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the healthcare sector in the People's Republic of China
(the "PRC"). The Group aims to leverage on investment opportunities
in the growing domestic demand for high quality healthcare products
in the PRC and build portfolio companies into market sector leaders
with competitive edge. Cathay has already demonstrated a track
record of identifying investment opportunities in this area
including: Lansen, a PRC specialty pharmaceutical company focused
on rheumatology and dermatology; Haizi, a PRC inositol
manufacturer; Natural Dailyhealth, a company engaged in production
and sales of plant extracts for use as key active ingredients in
healthcare products; and Botai, a company engaged in collagen
products.
The Group employs approximately 1,500 people across the PRC,
including over 20 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment in Shenzhen. For more
information please visit the Company's website:
http://www.cathay-intl.com.hk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFWFSEFUSEIM
(END) Dow Jones Newswires
June 12, 2019 06:59 ET (10:59 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024